Cargando…
Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo
Trachoma, caused by repeated ocular infection with Chlamydia trachomatis (Ct), is targeted for elimination as a public health problem. Serological testing for antibodies is promising for surveillance; determining useful thresholds will require collection of serological data from settings with differ...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012353/ https://www.ncbi.nlm.nih.gov/pubmed/33790370 http://dx.doi.org/10.1038/s41598-021-86639-8 |
_version_ | 1783673353214623744 |
---|---|
author | Gwyn, Sarah Awoussi, Marcel S. Bakhtiari, Ana Bronzan, Rachel N. Crowley, Kathryn Harding-Esch, Emma M. Kassankogno, Yao Kilangalanga, Janvier N. Makangila, Felix Mupoyi, Sylvain Ngondi, Jeremiah Ngoyi, Bonaventure Palmer, Stephanie Randall, Jessica M. Seim, Anders Solomon, Anthony W. Stewart, Raymond Togbey, Kwamy Uvon, Pitchouna A. Martin, Diana L. |
author_facet | Gwyn, Sarah Awoussi, Marcel S. Bakhtiari, Ana Bronzan, Rachel N. Crowley, Kathryn Harding-Esch, Emma M. Kassankogno, Yao Kilangalanga, Janvier N. Makangila, Felix Mupoyi, Sylvain Ngondi, Jeremiah Ngoyi, Bonaventure Palmer, Stephanie Randall, Jessica M. Seim, Anders Solomon, Anthony W. Stewart, Raymond Togbey, Kwamy Uvon, Pitchouna A. Martin, Diana L. |
author_sort | Gwyn, Sarah |
collection | PubMed |
description | Trachoma, caused by repeated ocular infection with Chlamydia trachomatis (Ct), is targeted for elimination as a public health problem. Serological testing for antibodies is promising for surveillance; determining useful thresholds will require collection of serological data from settings with different prevalence of the indicator trachomatous inflammation—follicular (TF). Dried blood spots were collected during trachoma mapping in two districts each of Togo and Democratic Republic of the Congo. Anti-Ct antibodies were detected by multiplex bead assay (MBA) and three different lateral flow assays (LFA) and seroprevalence and seroconversion rate (SCR) were determined. By most tests, the district with > 5% TF (the elimination threshold) had five–sixfold higher seroprevalence and tenfold higher SCR than districts with < 5% TF. The agreement between LFA and MBA was improved using a black latex developing reagent. These data show optimization of antibody tests against Ct to better differentiate districts above or below trachoma elimination thresholds. |
format | Online Article Text |
id | pubmed-8012353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80123532021-04-01 Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo Gwyn, Sarah Awoussi, Marcel S. Bakhtiari, Ana Bronzan, Rachel N. Crowley, Kathryn Harding-Esch, Emma M. Kassankogno, Yao Kilangalanga, Janvier N. Makangila, Felix Mupoyi, Sylvain Ngondi, Jeremiah Ngoyi, Bonaventure Palmer, Stephanie Randall, Jessica M. Seim, Anders Solomon, Anthony W. Stewart, Raymond Togbey, Kwamy Uvon, Pitchouna A. Martin, Diana L. Sci Rep Article Trachoma, caused by repeated ocular infection with Chlamydia trachomatis (Ct), is targeted for elimination as a public health problem. Serological testing for antibodies is promising for surveillance; determining useful thresholds will require collection of serological data from settings with different prevalence of the indicator trachomatous inflammation—follicular (TF). Dried blood spots were collected during trachoma mapping in two districts each of Togo and Democratic Republic of the Congo. Anti-Ct antibodies were detected by multiplex bead assay (MBA) and three different lateral flow assays (LFA) and seroprevalence and seroconversion rate (SCR) were determined. By most tests, the district with > 5% TF (the elimination threshold) had five–sixfold higher seroprevalence and tenfold higher SCR than districts with < 5% TF. The agreement between LFA and MBA was improved using a black latex developing reagent. These data show optimization of antibody tests against Ct to better differentiate districts above or below trachoma elimination thresholds. Nature Publishing Group UK 2021-03-31 /pmc/articles/PMC8012353/ /pubmed/33790370 http://dx.doi.org/10.1038/s41598-021-86639-8 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Gwyn, Sarah Awoussi, Marcel S. Bakhtiari, Ana Bronzan, Rachel N. Crowley, Kathryn Harding-Esch, Emma M. Kassankogno, Yao Kilangalanga, Janvier N. Makangila, Felix Mupoyi, Sylvain Ngondi, Jeremiah Ngoyi, Bonaventure Palmer, Stephanie Randall, Jessica M. Seim, Anders Solomon, Anthony W. Stewart, Raymond Togbey, Kwamy Uvon, Pitchouna A. Martin, Diana L. Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo |
title | Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo |
title_full | Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo |
title_fullStr | Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo |
title_full_unstemmed | Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo |
title_short | Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo |
title_sort | comparison of platforms for testing antibodies to chlamydia trachomatis antigens in the democratic republic of the congo and togo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012353/ https://www.ncbi.nlm.nih.gov/pubmed/33790370 http://dx.doi.org/10.1038/s41598-021-86639-8 |
work_keys_str_mv | AT gwynsarah comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT awoussimarcels comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT bakhtiariana comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT bronzanracheln comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT crowleykathryn comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT hardingeschemmam comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT kassankognoyao comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT kilangalangajanviern comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT makangilafelix comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT mupoyisylvain comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT ngondijeremiah comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT ngoyibonaventure comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT palmerstephanie comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT randalljessicam comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT seimanders comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT solomonanthonyw comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT stewartraymond comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT togbeykwamy comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT uvonpitchounaa comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo AT martindianal comparisonofplatformsfortestingantibodiestochlamydiatrachomatisantigensinthedemocraticrepublicofthecongoandtogo |